Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis

CNS Drugs

Volumn 26, Issue 1, 2012, Pages 11-37

  Gensicke, Henrik ^a   Leppert, David ^a   Yaldizli, Özgür ^a   Lindberg, Raija L P ^a   Mehling, Matthias ^a   Kappos, Ludwig ^a   Kuhle, Jens ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Alemtuzumab; Atacicept; Daclizumab; Monoclonal antibodies; Multiple sclerosis; Natalizumab; Ocrelizumab; Rituximab; Secukinumab; Tabalumab; Ustekinumab

Indexed keywords

AIN 457; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ATACICEPT; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CHIMERIC ANTIBODY; CORTICOSTEROID; DAC HYP; DAC PENZBERG; DACLIZUMAB; FENYRAMIDOL; GLATIRAMER; IMMUNOGLOBULIN; INFLIXIMAB; LY 2127399; METHOTREXATE; MODAFINIL; MONOCLONAL ANTIBODY; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; PLACEBO; RITUXIMAB; SECUKINUMAB; TABALUMAB; UNCLASSIFIED DRUG; USTEKINUMAB; VERY LATE ACTIVATION ANTIGEN 4;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ALLERGIC ENCEPHALOMYELITIS; ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; ANXIETY; APOPTOSIS; ARTHRALGIA; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; B CELL LYMPHOMA; B LYMPHOCYTE; BACKACHE; BREAST CANCER; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CELL MIGRATION; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; CROHN DISEASE; CRYOGLOBULINEMIA; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EFFUSION; EYE INFECTION; EYE SWELLING; FATIGUE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HOT FLUSH; HTLV 1 ASSOCIATED MYELOPATHY; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; INFECTION; INJECTION SITE REACTION; INSOMNIA; JC VIRUS; LEUKOCYTE; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MALAISE; MELANOMA; META ANALYSIS (TOPIC); MONOTHERAPY; MOTOR NEUROPATHY; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULAR PRURITUS; OPPORTUNISTIC INFECTION; OPSOCLONUS MYOCLONUS SYNDROME; PARAPROTEINEMIA; PERIPHERAL EDEMA; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUS CONGESTION; SINUSITIS; SJOEGREN SYNDROME; SKIN DISEASE; SORE THROAT; STIFF MAN SYNDROME; STOMATITIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LEUKEMIA; T LYMPHOCYTE; THROAT IRRITATION; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THYROID DISEASE; TOXOPLASMOSIS; TREATMENT RESPONSE; TROPICAL SPASTIC PARAPARESIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; UVEITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DRUG DELIVERY SYSTEMS; HUMANS; MULTIPLE SCLEROSIS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 83455186144     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11596920-000000000-00000     Document Type: Review

References (226)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359 (9313): 1221-31 (Pubitemid 34304266)
2. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13 (7): 700-22 (Pubitemid 44143944)
3. Rovaris M, Confavreux C, Furlan R, et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006; 5 (4): 343-54
4. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007; 6 (10): 903-12 (Pubitemid 47405002)
5. Girouard N, Theoret G. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis. Can J Neurosci Nurs 2008; 30 (4): 18-25
6. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60 (1): 44-51 (Pubitemid 36070642)
7. Montalban X. Overview of European pilot study of interferon beta-1b in primary progressive multiple sclerosis. Mult Scler 2004; 10 Suppl. 1: S62; discussion 62-4
8. Wolinsky JS, Shochat T, Weiss S, et al. Glatiramer acetate treatment in PPMS: why males appear to respond favorably. J Neurol Sci 2009; 286 (1-2): 92-8
9. Wolinsky JS. The PROMiSe trial: baseline data review and progress report. Mult Scler 2004; 10 Suppl. 1: S65-71; discussion S71-2
10. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59 (5): 679-87
11. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56 (11): 1496-504
12. Panitch H, Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63 (10): 1788-95 (Pubitemid 39532370)
13. European Study Group on interferon beta-1b in secondary progressive MS: placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352 (9139): 1491-7
14. Loo L, Robinson MK, Adams GP. Antibody engineering principles and applications. Cancer J 2008; 14 (3): 149-53
15. Calogiuri G, Ventura MT, Mason L, et al. Hypersensitivity reactions to last generation chimeric, humanized [correction of umanized] and human recombinant monoclonal antibodies for therapeutic use. Curr Pharm Des 2008; 14 (27): 2883-91
16. Mechetner E. Development and characterization of mouse hybridomas. Methods Mol Biol 2007; 378: 1-13
17. Hohlfeld R, Wekerle H. Drug insight: using monoclonal antibodies to treat multiple sclerosis. Nat Clin Pract Neurol 2005; 1 (1): 34-44
18. Monaco S, Turri E, Zanusso G, et al. Treatment of inflammatory and paraproteinemic neuropathies. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4 (2): 141-8
19. Briani C, Zara G, Zambello R, et al. Rituximab-responsive CIDP [letter]. Eur J Neurol 2004; 11 (11): 788
20. Finsterer J. Treatment of immune-mediated, dysimmune neuropathies. Acta Neurol Scand 2005; 112 (2): 115-25 (Pubitemid 41003372)
21. Kilidireas C, Anagnostopoulos A, Karandreas N, et al. Rituximab therapy in monoclonal IgM-related neuropathies. Leuk Lymphoma 2006; 47 (5): 859-64 (Pubitemid 43840641)
22. Gorson KC, Natarajan N, Ropper AH, et al. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007; 35 (1): 66-9 (Pubitemid 46052650)
23. Pranzatelli MR, Tate ED, Travelstead AL, et al. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics 2005; 115 (1): e115-9 (Pubitemid 43046272)
24. Burke MJ, Cohn SL. Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. Pediatr Blood Cancer 2008; 50 (3): 679-80 (Pubitemid 351155858)
25. Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonusmyoclonus syndrome. J Pediatr Hematol Oncol 2006; 28 (9): 585-93 (Pubitemid 44496336)
26. Ertle F, Behnisch W, Al Mulla NA, et al. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Pediatr Blood Cancer 2008; 50 (3): 683-7 (Pubitemid 351155860)
27. Leen WG, Weemaes CM, Verbeek MM, et al. Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome. Pediatr Neurol 2008; 39 (3): 213-7
28. Corapcioglu F, Mutlu H, Kara B, et al. Response to rituximab and prednisolone for opsoclonus-myoclonusataxia syndrome in a child with ganglioneuroblastoma. Pediatr Hematol Oncol 2008; 25 (8): 756-61
29. Pranzatelli MR, Tate ED, Travelstead AL, et al. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus. J Clin Immunol 2010; 30 (1): 106-13
30. Pranzatelli MR, Tate ED, Swan JA, et al. B cell depletion therapy for new-onset opsoclonus-myoclonus. Mov Disord 2010; 25 (2): 238-42
31. Pranzatelli MR, Tate ED, Verhulst SJ, et al. Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2010; 32 (5): e167-72
32. Bell J, Moran C, Blatt J. Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Pediatr Blood Cancer 2008; 50 (2): 370-1
33. Baek WS, BasheyA, SheeanGL. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis [letter]. J Neurol Neurosurg Psychiatry 2007; 78 (7): 771 (Pubitemid 46998860)
34. Zebardast N, Patwa HS, Novella SP, et al. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve 2010; 41 (3): 375-8
35. Lindberg C, Bokarewa M. Rituximab for severe myasthenia gravis: experience from five patients. Acta Neurol Scand 2010; 122 (4): 225-8
36. Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2010; 82 (6): 671-3
37. Hain B, Jordan K, Deschauer M, et al. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006; 33 (4): 575-80
38. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64 (7): 1270-2
39. Capobianco M, Malucchi S, di Sapio A, et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci 2007; 28 (4): 209-11 (Pubitemid 47263843)
40. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65 (11): 1443-8
41. Baker MR, Das M, Isaacs J, et al. Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatry 2005; 76 (7): 999-1001 (Pubitemid 40909562)
42. Venhoff N, Rizzi M, Salzer U, et al. Monozygotic twins with stiff person syndrome and autoimmune thyroiditis: rituximab inefficacy in a double-blind, randomised, placebo controlled crossover study. Ann Rheum Dis 2009; 68 (9): 1506-8
43. Dupond JL, Essalmi L, Gil H, et al. Rituximab treatment of stiff-person syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis. J Clin Neurosci 2010; 17 (3): 389-91
44. Katoh N, Matsuda M, Ishii W, et al. Successful treatment with rituximab in a patient with stiff-person syndrome complicated by dysthyroid ophthalmopathy. Intern Med 2010; 49 (3): 237-41
45. Bacorro EA, Tehrani R. Stiff-person syndrome: persistent elevation of glutamic acid decarboxylase antibodies despite successful treatment with rituximab. J Clin Rheumatol 2010; 16 (5): 237-9
46. Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132 (Pt 6): 1536-44
47. Ransohoff RM. Natalizumab for multiple sclerosis. NEngl J Med 2007; 356 (25): 2622-9 (Pubitemid 46961007)
48. Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993; 74 (1): 185-95 (Pubitemid 23219889)
49. Rudick RA, Sandrock A. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004; 4 (4): 571-80 (Pubitemid 38890585)
50. del PilarMM, Cravens PD, Winger R, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008; 65 (12): 1596-603
51. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005; 4 (6): 510-8 (Pubitemid 40861993)
52. Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59 (5): 748-54 (Pubitemid 43673152)
53. Tchilian EZ, Owen JJ, Jenkinson EJ. Anti-alpha 4 integrin antibody induces apoptosis in murine thymocytes and staphylococcal enterotoxin B-activated lymph node T cells. Immunology 1997; 92 (3): 321-7 (Pubitemid 27488142)
54. Lindberg RL, Achtnichts L, Hoffmann F, et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008; 194 (1-2): 153-64
55. Stuve O, Gold R, Chan A, et al. alpha4-Integrin antagonism with natalizumab: effects and adverse effects. J Neurol 2008; 255 Suppl. 6: 58-65
56. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356 (6364): 63-6
57. Tubridy N, Behan PO, Capildeo R, et al. The effect of antialpha4 integrin antibody on brain lesion activity inMS: the UKAntegren StudyGroup.Neurology 1999; 53 (3): 466-72 (Pubitemid 29382036)
58. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348 (1): 15-23 (Pubitemid 36026342)
59. Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebocontrolled study. Neurology 2009; 72 (9): 806-12
60. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354 (9): 911-23
61. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354 (9): 899-910
62. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, openlabel, phase I trial. Ann Neurol 2008; 63 (3): 395-400 (Pubitemid 351499869)
63. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358 (7): 676-88 (Pubitemid 351240747)
64. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66 (4): 460-71
65. Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010; 74 (23): 1860-7
66. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: results of a phase II randomized placebo-controlled multicenter trial. Lancet. Epub 2011 Oct 31
67. Soelberg Sorensen P, Drulovic J, Havrdova E, et al. Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing-remitting multiple sclerosis (RRMS): 24-week results of a phase II study [abstract no. 136 plus oral presentation]. Presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2010 Oct 13-16; Gothenburg
68. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359 (17): 1786-801
69. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9 (4): 381-90
70. Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relap-sing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7 (9): 796-804
71. Plitz T. Design of a four-arm, randomized, placebocontrolled phase II study of 36 weeks of atacicept monotherapy in relapsing multiple sclerosis [abstract]. Mult Scler 2008; 14 Suppl. 1: 173
72. Hartung HP. Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis. Nervenarzt 2009; 80 (12): 1462-72
73. Sergott R. Design of an exploratory two-arm, randomized, placebo controlled phase II study of 36 weeks of atacicept treatment in patients with optic neuritis as clinically isolated syndrome [abstract]. Mult Scler 2008; 14 Suppl. 1: 177
74. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007; 68 (17): 1390-401 (Pubitemid 46659091)
75. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8 (3): 254-60
76. O'Connor P, Goodman A, Kappos L, et al. The efficacy of natalizumab monotherapy over 3 years of treatment in patients with relapsing multiple sclerosis [abstract no. P06.082]. Presented at the 59th Annual Meeting of the American Academy of Neurology; 2007 Apr 28-May 5; Boston (MA)
77. O'Connor P, Polman C, Goodman A, et al. Efficacy and safety of natalizumab in the STRATA study [abstract no. P06.127]. Presented at the 61st Annual Meeting of the American Academy of Neurology; 2009 Apr 25-May 2; Seattle (WA)
78. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76 (22): 1858-65
79. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69 (14): 1391-403 (Pubitemid 47511460)
80. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353 (4): 369-74 (Pubitemid 41132341)
81. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353 (4): 375-81 (Pubitemid 41132342)
82. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.NEngl J Med 2005; 353 (4): 362-8 (Pubitemid 41132340)
83. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354 (9): 924-33
84. Panzara M, Belcher G, Kooijmans M, et al. Use of natalizumab in patients with relapsing multiple sclerosis: update safety results from TOUCH-and TYGRIS. Presented at the 23rd Congress of the European Commitee for the Treatment and Research in Multiple Sclerosis; 2007 Oct 11-14; Prague, 565
85. Bozic C, Belcher G, Kroojimans M, et al. The safety of natalizumab in patients with relapsing multiple sclerosis: an update from TOUCH-and TYGRIS [abstract no. P06.082]. Presented at the 59th Annual Meeting of the American Academy of Neurology; 2007 April 28-May 5; Boston (MA)
86. Biogen Idec.MedInfo [online]. Available fromURL: https://medinfo. biogenidec.com/medinfo/download?doc=Letter +Bodies%2Fnatalizumab+Safety+Update. pdf&type=pmldoc &Continue=Continue [Accessed 2011 Jun 30]
87. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10 (8): 745-58
88. Rudick RA, O'Connor PW, Polman CH, et al. Assessment of JC virus DNA in blood and urine from natalizumabtreated patients. Ann Neurol 2010; 68 (3): 304-10
89. Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361 (11): 1067-74
90. Sadiq SA, Puccio LM, Brydon EW. JCV detection in multiple sclerosis patients treated with natalizumab. J Neurol 2010; 257 (6): 954-8
91. Gorelik L, Goelz S, Sandrock AW. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361 (25): 2487-8
92. Jilek S, Jaquiery E, Hirsch HH, et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 2010; 9 (3): 264-72
93. Antonsson A, Green AC, Mallitt KA, et al. Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol 2010; 91 (Pt 7): 1849-53
94. Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199 (6): 837-46
95. Kean JM, Rao S, Wang M, et al. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009; 5 (3): e1000363
96. Knowles WA, Pipkin P, Andrews W, et al. Populationbased study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71 (1): 115-23 (Pubitemid 37121921)
97. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973; 127 (4): 467-70
98. Stolt A, Sasnauskas K, Koskela P, et al. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003; 84 (Pt 6): 1499-504 (Pubitemid 36675520)
99. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68 (3): 295-303
100. Goelz SE, Gorelik L, Subramanyam M. Assay design and sample collection can affect anti-John Cunningham virus antibody detection. Ann Neurol 2011; 69 (2): 429-30
101. Schweikert A, Kremer M, Ringel F, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009; 66 (3): 403-6
102. Bozic C, LaGuette J, Panzara MA, et al. Natalizumab and central nervous system lymphoma: no clear association. Ann Neurol 2009; 66 (3): 261-2
103. Zecca C, Nessi F, Bernasconi E, et al. Ocular toxoplasmosis during natalizumab treatment. Neurology 2009; 73 (17): 1418-9
104. Algazi AP, Kadoch C, Rubenstein JL. Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics 2009; 6 (3): 587-97
105. De AB, Dotti G, Quintarelli C, et al. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 2009; 114 (23): 4784-91
106. Finelli PF, Naik K, DiGiuseppe JA, et al. Primary lymphoma of CNS, mycophenolate mofetil and lupus. Lupus 2006; 15 (12): 886-8 (Pubitemid 46044922)
107. Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 2008; 358 (6): 647-8 (Pubitemid 351214309)
108. Panzara MA, Bozic C, Sandrock AW. More on melanoma with transdifferentiation.NEngl JMed 2008; 359 (1): 99-100
109. Bozic C, Christiano LM, Hyde R, et al. Utilisation and safety of natalizumab in patients with relapsing multiple sclerosis [abstract no. P893]. Mult Scler 2010; 16 Suppl. 10: S315
110. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 6 (5): 394-403
111. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002; 51 (1): 15-24 (Pubitemid 34158519)
112. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6 (4): 443-6 (Pubitemid 30208162)
113. Pedersen IM, Buhl AM, Klausen P, et al. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002; 99 (4): 1314-9 (Pubitemid 34547086)
114. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83 (2): 435-45 (Pubitemid 24030569)
115. Nadler LM, Stashenko P, Hardy R, et al. Characterization of a human B cell-specific antigen (B2) distinct from B1. J Immunol 1981; 126 (5): 1941-7 (Pubitemid 11120986)
116. Rieckmann P, Wilson GL, Thevenin C, et al. Analysis of cis-acting elements present in the CD20/B1 antigen promoter. J Immunol 1991; 147 (11): 3994-9
117. Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180 (1-2): 63-70 (Pubitemid 44767709)
118. Stuve O, Cepok S, Elias B, et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 2005; 62 (10): 1620-3 (Pubitemid 41434570)
119. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B-and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010; 67 (6): 707-14
120. Ruhstaller TW, Amsler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol 2000; 11 (3): 374-5 (Pubitemid 30214681)
121. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101 (2): 466-8 (Pubitemid 36077565)
122. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54 (9): 2793-806 (Pubitemid 44497758)
123. Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006; 66 (6): 791-820 (Pubitemid 43778729)
124. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350 (25): 2572-81 (Pubitemid 38758544)
125. Berentsen S, Ulvestad E, Langholm B, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 2006; 91 (4): 460-6
126. Gurcan HM, Keskin DB, Stern JN, et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009; 9 (1): 10-25
127. Kotani T, Takeuchi T, Kawasaki Y, et al. Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. Lupus 2006; 15 (10): 683-5 (Pubitemid 44682831)
128. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52 (9): 2740-50 (Pubitemid 41369102)
129. Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003; 101 (10): 3818-26 (Pubitemid 36857852)
130. Shanafelt TD, Madueme HL, Wolf RC, et al. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003; 78 (11): 1340-6 (Pubitemid 37337779)
131. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66 (4): 470-5 (Pubitemid 46580466)
132. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007; 40 (3): 273-7 (Pubitemid 47108472)
133. Collins-Burow B, Santos ES. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Expert Rev Anticancer Ther 2007; 7 (3): 257-73 (Pubitemid 46499210)
134. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 'what do B-cells do?'. Clin Immunol 2005; 117 (3): 207-13 (Pubitemid 43005207)
135. Monson NL, Cravens PD, Frohman EM, et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005; 62 (2): 258-64 (Pubitemid 40204747)
136. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010; 67 (4): 452-61
137. Carson KR, Bennett CL. Rituximab and progressive multifocal leukoencephalopathy: the jury is deliberating. Leuk Lymphoma 2009; 50 (3): 323-4
138. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10 (8): 816-24
139. Data on file, Hoffmann-La Roche, 2010
140. Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, doseranging study. Arthritis Rheum 2008; 58 (9): 2652-61
141. Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. Biodrugs 2011; 25 (1): 13-25
142. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276 (9): 6591-604
143. Roche. Roche and Biogen Idec decide to suspend ocrelizumab treatment: rheumatoid arthritis development programme on hold [media release]. 2010 Mar 8 [online]. Available from URL: http://www.roche.com/media/media-releases/med-cor- 2010-03-08.htm[Accessed 2011 Jun 30]
144. Emery P, Rigby W, Tak PP, et al. Serious infections with ocrelizumab in rheumatoid arthritis: pooled results from double-blind periods of the ocrelizumab phase III RA program [abstract]. Arthritis Rheum 2010; 62 Suppl. 10: 414
145. van Meerten T, Rozemuller H, Hol S, et al. HuMab-7D8, a monoclonal antibody directed against the membraneproximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist rituximab mediated lysis. Haematologica 2010; 95 (12): 2063-71
146. Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Des Devel Ther 2009; 3: 7-16
147. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 2010; 28 (21): 3525-30
148. Ostergaard M, Baslund B, Rigby W, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 2010; 62 (8): 2227-38
149. Ostergaard M, Wiell C, Dawes P, et al. First clinical results of HuMAx-CD20 fully human monoclonal IGG1 antibody treatment in rheumatoid arthritis [abstract no. P0018]. Ann Rheum Dis 2006; 65 Suppl. 2: 58
150. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111 (3): 1094-100 (Pubitemid 351213387)
151. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008; 111 (12): 5486-95
152. Genmab. A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients [ClinicalTrials.gov identifier NCT00640328]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Mar 18]
153. GlaxoSmithKline. GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications [media release]. 2010 Sep 16 [online]. Available from URL: http://www.gsk.com/media/press releases/2010/2010- pressrelease-10098.htm [Accessed 2011 Jun 30]
154. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82 (3): 807-12 (Pubitemid 23221659)
155. RiechmannL,ClarkM,WaldmannH, et al.Reshaping human antibodies for therapy. Nature 1988; 332 (6162): 323-7 (Pubitemid 18091075)
156. Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005; 35 (11): 3332-42 (Pubitemid 41672537)
157. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354 (9191): 1691-5 (Pubitemid 29533060)
158. Coles AJ, Cox A, Le PE, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253 (1): 98-108 (Pubitemid 43157395)
159. Thompson SA, Jones JL, Cox AL, et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 2010; 30 (1): 99-105
160. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46 (3): 296-304 (Pubitemid 29416266)
161. Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994; 344 (8918): 298-301 (Pubitemid 24230297)
162. Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011; 77 (6): 573-9
163. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119 (7): 2052-61
164. Genzyme. Comparison of Alemtuzumab and Rebif-Efficacy in Multiple Sclerosis, Study One (CARE-MS I). [Clinical Trials.gov identifier NCT00530348] US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 30]
165. Genzyme. Comparison of Alemtuzumab and Rebif-Efficacy in Multiple Sclerosis, Study Two (CARE-MS II). [Clinical Trials.gov identifier NCT00548405] US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 30]
166. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal anti-body in human renal transplantation. Transplant Proc 1991; 23 (1 Pt 2): 1066-7
167. Martin R. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis. Neurodegener Dis 2008; 5 (1): 23-6 (Pubitemid 350261812)
168. Waldmann TA, Longo DL, Leonard WJ, et al. Interleukin 2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemia. Cancer Res 1985; 45 (9 Suppl.): 4559s-62s (Pubitemid 16223294)
169. Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells: I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 1981; 126 (4): 1393-7 (Pubitemid 11149233)
170. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103 (15): 5941-6
171. Waldmann TA, O'Shea J. The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998; 10 (5): 507-12 (Pubitemid 28479180)
172. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008; 26: 453-79 (Pubitemid 351600382)
173. Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009; 66 (4): 483-9
174. Sandrini S. Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin Transplant 2005; 19 (5): 705-10 (Pubitemid 41748720)
175. Lehky TJ, Levin MC, Kubota R, et al. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol 1998; 44 (6): 942-7 (Pubitemid 28558256)
176. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 1999; 96 (13): 7462-6 (Pubitemid 29299684)
177. Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 2007; 27 (1): 1-18 (Pubitemid 46224930)
178. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004; 101 (23): 8705-8 (Pubitemid 38745835)
179. Rose JW, Watt HE, White AT, et al. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004; 56 (6): 864-7 (Pubitemid 39578450)
180. Rose JW, Burns JB, Bjorklund J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007; 69 (8): 785-9 (Pubitemid 47300936)
181. Biogen Idec. Efficacy and safety of daclizumab high yield process versus interferon b 1a in patients with relapsingremitting multiple sclerosis. [Clinical Trials.gov identifier NCT01064401] US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://www.clini caltrials.gov [Accessed 2011 Jun 30]
182. Ali EN, Healy BC, Stazzone LA, et al. Daclizumab in treatment of multiple sclerosis patients. Mult Scler 2009; 15 (2): 272-4
183. Sabatine MS, Poh KK, Mega JL, et al. Case records of the Massachusetts General Hospital. Case 36-2007: a 31-yearold woman with rash, fever, and hypotension. N Engl J Med 2007; 357 (21): 2167-78
184. Brok HP, van Meurs M, Blezer E, et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol 2002; 169 (11): 6554-63 (Pubitemid 36903508)
185. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421 (6924): 744-8 (Pubitemid 36227625)
186. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201 (2): 233-40 (Pubitemid 40189432)
187. Li Y, Chu N, Hu A, et al. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 2007; 130 (Pt 2): 490-501 (Pubitemid 46181102)
188. Vaknin-Dembinsky A, Balashov K, Weiner HL. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 2006; 176 (12): 7768-74 (Pubitemid 43849078)
189. Windhagen A, Newcombe J, Dangond F, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995; 182 (6): 1985-96
190. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13 (5): 715-25
191. Trinchieri G, Scott P. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Res Immunol 1995; 146 (7-8): 423-31 (Pubitemid 26054833)
192. Kikly K, Liu L, Na S, et al. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006; 18 (6): 670-5 (Pubitemid 44635178)
193. 't Hart BA, Brok HP, Remarque E, et al. Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody. J Immunol 2005; 175 (7): 4761-8 (Pubitemid 41362018)
194. Constantinescu CS, Wysocka M, Hilliard B, et al. Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J Immunol 1998; 161 (9): 5097-104 (Pubitemid 28492093)
195. Kasper LH, Everitt D, Leist TP, et al. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin 2006; 22 (9): 1671-8 (Pubitemid 44449223)
196. Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev Neurother 2009; 9 (3): 319-21
197. Segal BM, Shevach EM. IL-12 unmasks latent autoimmune disease in resistant mice. J Exp Med 1996; 184 (2): 771-5 (Pubitemid 26324133)
198. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404 (6781): 995-9 (Pubitemid 30243593)
199. Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15 (2): 289-302 (Pubitemid 32816877)
200. Schneider P, Mackay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189 (11): 1747-56 (Pubitemid 29272691)
201. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005; 17 (3): 282-9 (Pubitemid 40692663)
202. Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005; 201 (2): 195-200 (Pubitemid 40189428)
203. Thangarajh M, Masterman T, Rot U, et al. Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J Neuroimmunol 2005; 167 (1-2): 210-4 (Pubitemid 41242304)
204. Marsters SA, Yan M, Pitti RM, et al. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000; 10 (13): 785-8 (Pubitemid 30466942)
205. Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebocontrolled, dose-escalating trial. Arthritis Rheum 2007; 56 (12): 4142-50 (Pubitemid 350262342)
206. Kalled SL. The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 2005; 204: 43-54 (Pubitemid 40460492)
207. Munafo A, Priestley A, Nestorov I, et al. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 2007; 63 (7): 647-56 (Pubitemid 46911347)
208. Nestorov I, Munafo A, Papasouliotis O, et al. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 2008; 48 (4): 406-17 (Pubitemid 351389119)
209. Tak PP, ThurlingsRM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, singleand repeated-dose study. Arthritis Rheum 2008; 58 (1): 61-72
210. Pena-Rossi C, Nasonov E, Stanislav M, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 2009; 18 (6): 547-55
211. EMD Serono. Atacicept in combination with rituximab in subjects with rheumatoid arthritis (August III). [Clinical Trials.gov identifier NCT00664521] US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 30]
212. GenoveseMC. Phase 2 study of safety and efficacy of a novel anti-BAFF monoclonal antibody, in patients with RA treated with methotrexate (MTX). ACR/ARHP 2009 Annual Scientific Meeting; 2009 Oct 17-21; Philadelphia (PA)
213. Eli Lilly and Company. A study of patients with relapsing remitting multiple sclerosis. [Clinical Trials.gov identifier NCT00882999] US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://www.clini caltrials.gov [Accessed 2011 Jun 30]
214. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2 (52): 52ra72
215. Novartis Pharmaceuticals. A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity (MRI scans) in patients with relapsing-remitting multiple sclerosis [ClinicalTrials.gov identifier NCT01051817]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jan 19]
216. Hausmann OV, Seitz M, Villiger PM, et al. The complex clinical picture of side effects to biologicals. Med Clin North Am 2010; 94 (4): 791-804, xi-ii
217. Wiendl H, Neuhaus O, Kappos L, et al. Multiple sclerosis: current review of failed and discontinued clinical trials of drug treatment. Nervenarzt 2000; 71 (8): 597-610 (Pubitemid 30641338)
218. Hohlfeld R, Wiendl H. The ups and downs of multiple sclerosis therapeutics. Ann Neurol 2001; 49 (3): 281-4 (Pubitemid 32202778)
219. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. Biodrugs 2002; 16 (3): 183-200 (Pubitemid 34852318)
220. Kappos L, Radue EW, O'Connor P, et al. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362 (5): 387-401
221. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362 (5): 402-15
222. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371 (9630): 2085-92 (Pubitemid 351842581)
223. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372 (9648): 1463-72
224. Miller D, Weber T, Montalban X, et al. Phase II trial of firategrast shows that oral anti-alpha4 therapy can suppress new MRI lesions in relapsing-remitting multiple sclerosis [abstract no. 113 plus oral presentation]. Presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2010 Oct 13-16; Gothenburg
225. O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66 (6): 894-900 (Pubitemid 43739766)
226. Miller A, O'Connor P, Wolinsky JS, et al. Clinical and MRI outcomes from a phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses [abstract no. S41.002]. Program and abstracts of the American Academy of Neurology (AAN) 63rd Annual Meeting; 2011 Apr 9-16; Honolulu (HI)